vs

Side-by-side financial comparison of Capital Bancorp Inc (CBNK) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $62.7M, roughly 1.2× Capital Bancorp Inc). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 11.6%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 23.7%).

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CBNK vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.2× larger
PBYI
$75.5M
$62.7M
CBNK
Growing faster (revenue YoY)
PBYI
PBYI
+16.2% gap
PBYI
27.7%
11.6%
CBNK
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
23.7%
CBNK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CBNK
CBNK
PBYI
PBYI
Revenue
$62.7M
$75.5M
Net Profit
Gross Margin
69.3%
Operating Margin
31.4%
22.7%
Net Margin
Revenue YoY
11.6%
27.7%
Net Profit YoY
EPS (diluted)
$0.92
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBNK
CBNK
PBYI
PBYI
Q4 25
$62.7M
$75.5M
Q3 25
$63.1M
$54.5M
Q2 25
$60.8M
$52.4M
Q1 25
$58.6M
$46.0M
Q4 24
$56.2M
$59.1M
Q3 24
$45.0M
$80.5M
Q2 24
$43.9M
$47.1M
Q1 24
$41.0M
$43.8M
Net Profit
CBNK
CBNK
PBYI
PBYI
Q4 25
Q3 25
$15.1M
$8.8M
Q2 25
$13.1M
$5.9M
Q1 25
$13.9M
$3.0M
Q4 24
Q3 24
$8.7M
$20.3M
Q2 24
$8.2M
$-4.5M
Q1 24
$6.6M
$-4.8M
Gross Margin
CBNK
CBNK
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
CBNK
CBNK
PBYI
PBYI
Q4 25
31.4%
22.7%
Q3 25
-1.5%
17.6%
Q2 25
-1.5%
12.7%
Q1 25
-1.5%
8.7%
Q4 24
-2.2%
22.6%
Q3 24
-2.2%
27.4%
Q2 24
-1.8%
-4.6%
Q1 24
-2.3%
-5.3%
Net Margin
CBNK
CBNK
PBYI
PBYI
Q4 25
Q3 25
23.9%
16.2%
Q2 25
21.6%
11.2%
Q1 25
23.8%
6.5%
Q4 24
Q3 24
19.3%
25.2%
Q2 24
18.7%
-9.6%
Q1 24
16.0%
-11.0%
EPS (diluted)
CBNK
CBNK
PBYI
PBYI
Q4 25
$0.92
$0.26
Q3 25
$0.89
$0.17
Q2 25
$0.78
$0.12
Q1 25
$0.82
$0.06
Q4 24
$0.44
$0.40
Q3 24
$0.62
$0.41
Q2 24
$0.59
$-0.09
Q1 24
$0.47
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBNK
CBNK
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$401.8M
$130.3M
Total Assets
$3.6B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBNK
CBNK
PBYI
PBYI
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
CBNK
CBNK
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
CBNK
CBNK
PBYI
PBYI
Q4 25
$401.8M
$130.3M
Q3 25
$394.8M
$115.3M
Q2 25
$380.0M
$104.7M
Q1 25
$369.6M
$97.1M
Q4 24
$355.1M
$92.1M
Q3 24
$280.1M
$71.1M
Q2 24
$267.9M
$48.5M
Q1 24
$259.5M
$51.0M
Total Assets
CBNK
CBNK
PBYI
PBYI
Q4 25
$3.6B
$216.3M
Q3 25
$3.4B
$202.9M
Q2 25
$3.4B
$194.9M
Q1 25
$3.3B
$196.2M
Q4 24
$3.2B
$213.3M
Q3 24
$2.6B
$220.7M
Q2 24
$2.4B
$205.0M
Q1 24
$2.3B
$214.1M
Debt / Equity
CBNK
CBNK
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBNK
CBNK
PBYI
PBYI
Operating Cash FlowLast quarter
$69.7M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBNK
CBNK
PBYI
PBYI
Q4 25
$69.7M
$14.4M
Q3 25
$32.9M
$9.7M
Q2 25
$-4.2M
$14.1M
Q1 25
$22.6M
$3.6M
Q4 24
$34.9M
$15.6M
Q3 24
$-464.0K
$11.0M
Q2 24
$12.9M
$1.0M
Q1 24
$-3.4M
$11.2M
Free Cash Flow
CBNK
CBNK
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
CBNK
CBNK
PBYI
PBYI
Q4 25
19.1%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
CBNK
CBNK
PBYI
PBYI
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
CBNK
CBNK
PBYI
PBYI
Q4 25
Q3 25
2.18×
1.10×
Q2 25
-0.32×
2.41×
Q1 25
1.62×
1.21×
Q4 24
Q3 24
-0.05×
0.54×
Q2 24
1.57×
Q1 24
-0.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons